Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q425
Rhea-AI Summary
Alpha Cognition (NASDAQ: ACOG) saw accelerating commercial traction for ZUNVEYL at the end of FY25. 4Q25 net product revenue reached $2.5M and FY25 revenue was $10.2M, including $6.8M from ZUNVEYL. Bottles dispensed rose 62% q/q to 4,941, with December at a record 1,859.
Adoption metrics show 729 ordering homes and 865 prescribers, with repeat orders at 82% and repeat writers at 69%. The company ended FY25 with $66.0M cash, which management says funds commercialization into 2027 and supports expected sequential sales growth in 2026.
Positive
- 4Q25 product sales of $2.5M
- FY25 revenue of $10.2M with $6.8M ZUNVEYL sales
- Bottles dispensed +62% q/q to 4,941
- $66.0M cash runway into 2027
- 82% repeat ordering across 729 homes
Negative
- None.
News Market Reaction – ACOG
On the day this news was published, ACOG gained 8.56%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.5% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $11M to the company's valuation, bringing the market cap to $140.73M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ACOG gained 3.2% with strong volume. Peers showed mixed moves: MIST up 12.26%, GLSI up 8.2%, SGMO and AGEN modestly higher, while MCRB fell 1.72%. Only one peer appeared in momentum scans, pointing to a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Earnings results | Positive | -4.9% | Reported FY25 revenue of $10.2M and strong ZUNVEYL growth metrics. |
| Mar 13 | Earnings date set | Neutral | -1.7% | Announced timing of Q4 and FY25 earnings release and conference call. |
| Mar 10 | Clinical data plans | Positive | +0.3% | Planned multiple ZUNVEYL clinical data presentations at upcoming conferences. |
| Feb 25 | Study enrollment | Positive | +5.4% | First patient enrolled in BEACON Phase 4 real-world effectiveness study. |
| Feb 18 | Patent issuance | Positive | +11.3% | USPTO issued new patent covering benzgalantamine dosing regimens for ZUNVEYL. |
Recent fundamentally positive updates have often seen mixed to positive price reactions, with one notable selloff on strong earnings metrics.
Over the last several months, Alpha Cognition has built a story around ZUNVEYL’s commercial and clinical progress. On Feb 18, a new U.S. patent extended protection to July 2045, followed by the BEACON Phase 4 study first-patient enrollment on Feb 25. March brought conference presentation plans and fiscal 2025 results showing $10.2M revenue and growing bottle volumes. Today’s coverage update largely reiterates those metrics while emphasizing durability of long-term care adoption and cash runway into 2027.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Aug 22, 2025 provides Alpha Cognition with registered capital-raising flexibility, with disclosed potential dilution from warrants, preferred conversions, and options, but no specific aggregate shelf size stated in the summary.
Market Pulse Summary
The stock moved +8.6% in the session following this news. A strong positive reaction aligns with the article’s emphasis on durable ZUNVEYL traction: 4Q25 net product revenue of $2.5M, FY25 revenue of $10.2M, and a 62% QoQ increase to 4,941 bottles dispensed. The company also reported $66.0M in cash and runway into 2027. With an active Form S-3 shelf, investors have previously faced potential dilution risk from future capital raises.
AI-generated analysis. Not financial advice.
Dallas, Texas--(Newsfile Corp. - April 1, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition exited FY25 with ZUNVEYL showing increasingly durable traction in long-term care, as 4Q25 net product revenue reached
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- ZUNVEYL adoption is becoming durable. 4Q25 sales hit
$2.5M , bottles dispensed rose62% q/q to 4,941, and December reached 1,859. - LTC traction is strengthening with repeat behavior. 729 ordering homes,
82% repeat orders, and 865 prescribers with69% repeat writers support protocol adoption. - ACOG is funded to keep scaling commercialization. Ended FY25 with
$66.0M cash, runway into 2027, and expects continued sequential sales growth in 2026.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290861
FAQ
What were Alpha Cognition (ACOG) 4Q25 and FY25 revenue figures?
How fast is ZUNVEYL adoption growing for Alpha Cognition (ACOG)?
How many facilities and prescribers are using ZUNVEYL as of FY25 for ACOG?
What is Alpha Cognition's cash position and runway after FY25 (ACOG)?
What sales outlook did Alpha Cognition (ACOG) give for 2026?
